POSTMOLAR TROPHOBLASTIC DISEASE IN WOMEN USING HORMONAL CONTRACEPTION WITH AND WITHOUT ESTROGEN

  • 1 January 1983
    • journal article
    • research article
    • Vol. 62  (6) , 736-740
Abstract
Patients (113) with a molar pregnancy evacuated during 1976-1980, were followed up. Twenty-seven patients (23.9%) developed postmolar trophoblastic disease, all of whom achieved remission with treatment. Of the 113 patients, 71 (62.8%) used only oral contraceptives, 32 patients (28.3%) used only i.m. medroxyprogesterone acetate, 7 patients (6.2%) used both oral contraceptives and medroxyprogesterone acetate, and 3 patients (2.7%) used nonhormonal contraception after evacuation of their molar pregnancy and before [human chorionic gonadotropin] titer remission. Analysis of significant clinical and laboratory correlates of postmolar trophoblastic disease for the study group revealed no substantial bias in assignment of contraceptive method. There was no significant difference between the oral contraceptive and the medroxyprogesterone acetate groups with respect to the development of postmolar trophoblastic disease or the time to spontaneous titer remisison. No apparent adverse effect of the estrogen (50 mg mestranol) component in oral contraceptives on the frequency of postmolar trophoblastic disease was observed.

This publication has 2 references indexed in Scilit: